GET DAILY SIGNALSAlvotech (ALVO): A Focused Play on Biosimilars
Key Takeaways
- ALVO is the Nasdaq ticker for Alvotech, a global biopharmaceutical company focused exclusively on developing and manufacturing biosimilar medicines.
- A biosimilar is a highly similar, lower-cost version of an already-approved biologic medicine, such as Humira or Stelara.
- Founded in 2013 and registered in Luxembourg, Alvotech runs its main manufacturing and R&D operations in Reykjavik, Iceland.
- The company has five approved biosimilars on the market and an industry-leading pipeline of roughly 30 additional candidates in development.
- Alvotech commercializes its products through a network of partners, including Teva (TEVA), STADA, and Advanz Pharma, across markets spanning the U.S., Europe, Japan, and beyond.
Introduction
Alvotech (ALVO) stands out as a biotechnology company built entirely around biosimilars. These are medicines that closely match already-approved biologic drugs but typically come at a lower price, improving access to costly treatments. I have been following ALVO because it is one of the few pure-play companies in this space, with an integrated platform covering research, development, and manufacturing.
Company Overview and Business Model
Alvotech was founded in 2013 by Robert Wessman, an executive with extensive experience in biologics and biosimilars. The company is registered in Luxembourg, but its core research, development, and manufacturing take place in Reykjavik, Iceland. Shares trade on Nasdaq under ALVO, with Swedish Depositary Receipts also listed on Nasdaq Stockholm. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The business follows a fully integrated, end-to-end model. Alvotech handles cell line development, process engineering, clinical studies, regulatory filings, and commercial-scale manufacturing in-house rather than outsourcing. This approach helps control quality, costs, and capacity across the portfolio.
Revenue comes from two primary sources: product sales of approved biosimilars through commercial partners and license revenue that includes upfront and milestone payments. Because milestones arrive irregularly, quarterly revenue can vary.
Marketed products include biosimilars referencing several major biologics:
- A biosimilar to Humira (adalimumab), sold in the U.S. as SIMLANDI, for conditions such as rheumatoid arthritis and Crohn’s disease.
- A biosimilar to Stelara (ustekinumab), sold in the U.S. as SELARSDI, for psoriasis and related diseases.
- Biosimilars referencing Simponi (golimumab), Eylea (aflibercept), and Prolia/Xgeva (denosumab).
The pipeline targets autoimmune disorders, eye disorders, bone disorders, respiratory disease, and cancer.
Alvotech does not handle large-scale commercialization on its own in most markets. Instead, it works with partners such as Teva (TEVA) in the United States, STADA in Europe, Fuji Pharma in Japan, and Advanz Pharma along with others elsewhere. This model supports reach into roughly 90 countries while keeping internal focus on development and manufacturing.
Why Investors Follow ALVO
Alvotech represents a concentrated way to participate in the expanding global biosimilars market. As healthcare systems look to manage spending on high-cost biologics, demand for more affordable alternatives continues to grow. From what I see, the company’s fully integrated manufacturing platform provides a competitive edge in a field where reliable, high-quality production is both technically challenging and capital intensive. The portfolio features first-wave and, in some cases, interchangeable biosimilars to major reference products, which can offer early-mover benefits. A diversified pipeline of roughly 30 candidates is designed to support ongoing launches and revenue growth.
Financially, the profile has shifted from heavy investment and losses toward a steadier combination of product sales and milestone income. Key areas to watch include gross margin expansion, R&D spending control, and production scaling on the path to sustained profitability.
Key Risks and Considerations
Investing in Alvotech carries notable risks tied to both the industry and the company’s stage of development. The biosimilars space is competitive, with both other developers and original biologic makers vying for share on price and volume. Regulatory approvals are not assured, and past manufacturing observations at the Reykjavik facility have delayed certain U.S. approvals.
The company depends heavily on partners for market access, pricing, and launches, so any issues with a key partner could affect results. Manufacturing and supply chain reliability remain critical, as disruptions can limit availability and delay rollouts. Alvotech also carries substantial debt and has posted net losses during periods of pipeline investment, which can pressure the balance sheet. Broader factors such as interest rates, currency fluctuations, and trade policy add further layers of exposure in a regulated sector.
Using AI Tools in My Research
When screening for comparable opportunities across thousands of stocks, I often turn to Tickeron’s AI Screener. This AI-powered platform lets me apply technical indicators, fundamentals, volatility measures, trends, AI signals, industry filters, and price patterns to surface ideas that align with specific strategies. It has become a practical part of reviewing names like ALVO efficiently.
Conclusion
Alvotech offers a pure-play exposure to biosimilars through its integrated platform, five marketed products, and broad pipeline aimed at major therapeutic areas. The partnership model and global footprint place it within a growing market for more affordable biologics, though reliance on partners, manufacturing execution, and regulatory outcomes remain important factors. In my view, it provides a focused lens on long-term biosimilar adoption while balancing the operational and financial risks typical of the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALVO's RSI Indicator ascending out of oversold territory
The RSI Oscillator for ALVO moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 27 of the 34 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 64 cases where ALVO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ALVO as a result. In 66 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for ALVO just turned positive on November 10, 2026. Looking at past instances where ALVO's MACD turned positive, the stock continued to rise in 34 of 48 cases over the following month. The odds of a continued upward trend are 71%.
Following a +4.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for ALVO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.057) is normal, around the industry mean (6.379). P/E Ratio (-7.839) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement